Skip to main content
logo
Seoul Pharma Co., Ltd (KOSDAQ:018680)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,991.00
-24.00 (-1.19%)
At close: Jul 31, 2026

Seoul Pharma Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
51,32752,14953,58052,45950,05740,463
Revenue Growth
-3.22%-2.67%2.14%4.80%23.71%-22.53%
Gross Profit
30,89131,50332,92931,58832,14625,483
Operating Income
-1,350-1,2791,5281,2131,739-5,713
Net Income
725.89753.641,6993,517855.09-9,689
Earnings Per Share
62.2664.64145.69301.6895.23-1136.55
EPS Growth
-22.91%-55.63%-51.71%216.80%--

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
18,1269,9497,5409,66411,72813,820
Total Debt
17,22317,39216,12610,95614,94729,383
Net Cash (Debt)
903.78-7,443-8,586-1,292-3,219-15,563
Net Cash Growth
------
Net Cash Per Share
77.52-638.40-736.44-110.83-358.47-1825.71

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
10,9531,886-3,0085,265-78.21-1,675
Capital Expenditures
-910.37-861.26-2,229-1,893-1,233-1,157
Free Cash Flow
10,0421,025-5,2373,372-1,311-2,831
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
60.18%60.41%61.46%60.21%64.22%62.98%
Operating Margin
-2.63%-2.45%2.85%2.31%3.47%-14.12%
Pretax Margin
1.32%1.21%3.29%7.71%-2.24%-23.71%
Profit Margin
1.41%1.44%3.17%6.71%1.71%-23.95%
FCF Margin
19.56%1.97%-9.78%6.43%-2.62%-7.00%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
31.9847.6522.7212.7068.58-
P/FCF Ratio
2.3135.05-13.24--
PS Ratio
0.450.690.720.851.171.65